Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders

Expert Review of Neurotherapeutics

Volumn 11, Issue 11, 2011, Pages 1509-1523

  Jankovic, Joseph ^a   Clarence Smith, Kathleen ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b KM Pharmaceuticals Consulting   (United States)

Author keywords

chorea; Huntington's disease; tardive dyskinesia; tetrabenazine; Tourette's syndrome; VMAT2 inhibition

Indexed keywords

CARBONYL REDUCTASE; PLACEBO; TETRABENAZINE;

AKATHISIA; ANXIETY; ARTICLE; ASPIRATION PNEUMONIA; AUTOMUTILATION; BALANCE IMPAIRMENT; BRADYKINESIA; CHOREA; CONFUSION; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; DYSPHAGIA; ECCHYMOSIS; FALLING; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; HYPERPYREXIA; HYPERSALIVATION; HYPOTENSION; INSOMNIA; IRRITABILITY; LIVER FUNCTION TEST; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSONISM; PHARMACODYNAMICS; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SWEATING; TARDIVE DYSKINESIA; TIC; UPPER RESPIRATORY TRACT INFECTION; VOCAL TIC; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; CHOREA; HUMANS; HYPERKINESIS; TETRABENAZINE;

EID: 80054893761     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.149     Document Type: Article

References (109)

1. Pletscher A, Brossi A, Gey KF. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int. Rev. Neurobiol. 4, 275-306 (1962)
2. Carlsson A. Drugs which block the storage of 5-hydroxy-tryptamine and related amines. Handbook Exp. Pharmacol. 19, 529-592 (1965)
3. Gardner M, Hawkins HM, Judah LN, Murphree OD. Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia. Psychiatric Res. Rep. 1, 77-83 (1955)
4. Shepherd M, Watt D. A controlled clinical study of chlorpromazine and reserpine in chronic schizophrenia. J Neurol. Neurosurg. Psychiatry 19, 232 (1956)
5. Moore JN, Martin EA. Trial of reserpine in treatment of schizophrenia. Br. Med. J 5, 8-14 (1957)
6. Ashcroft GW, Macdougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J Ment. Sci. 107, 287-293 (1961)
7. Brandrup E. [Reserpine and tetrabenazine for Huntington's chorea]. Nordisk Medicin 4(8), 968-969 (1960)
8. Sattes H, Hase E. [The Treatment of extrapyramidal hyperkinesia with special consideration of Huntington's chorea]. Psychiat. Neurol. Neurochir. 67, 289-298 (1964)
9. Stumpf W. [Studies on 'Nitoman']. Psychiat. Neurol. 140, 63-68 (1960)
10. Gilligan BS, Wodak J, Veale J, Munro OR. Tetrabenazine in the treatment of extrapyramidal dyskinesias. Med. J Aust. 2(19), 1054-1056 (1972)
11. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1(7848), 104-107 (1974)
12. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 31(8), 1051-1053 (1981)
13. Shoulson I, Goldblatt D. Huntington's disease (HD): effect of tetrabenazine and antipsychotic drugs on motoric features. Neurology 31, 79 (1981)
14. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 8, 844-856 (2009)
15. Frank S; Huntington Study Group. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurology 9, 62-72 (2009)
16. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98 (2011)
17. Krobitsch S, Kazantsev AG. Huntington's disease: from molecular basis to therapeutic advances. Int. J Biochem. Cell Biol. 43(1), 20-24 (2011)
18. de Tommaso M, Serpino C, Sciruicchio V. Management of Huntington's disease: role of tetrabenazine. Ther. Clin. Risk Manag. 7, 123-129 (2011)
19. McLellan DL. The suppression of involuntary movements with tetrabenazine. Scot. Med. J 17, 367 (1972)
20. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double blind crossover study. Ann Neurol. 11(1), 41-47 (1982)
21. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics and other dyskinesias. Neurology 38, 391-394 (1988)
22. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48(2), 358-362 (1997)
23. Astin KJ, Gumpert EW. Letter: tetrabenazine in chorea. Lancet 23, 1(7856), 512 (1974)
24. Kingston D. Tetrabenazine for involuntary movement disorders. Med. J Aust. 1(13), 628-630 (1979)
25. Mikkelsen B. Tolerance of tetrabenazine during long-term treatment. Acta Neurol. Scand. 68, 57-60 (1983)
26. Marshall F; Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66, 366-372 (2006)
27. Marshall F, Eberly S, Shoulson I, Clarence-Smith K. Antidepressant treatment does not affect the anti-chorea efficacy of tetrabenazine in TetraHD, a double-blind placebo-controlled trial. Neurotherapeutics (2011) (In press)
28. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev. Neurother. 6, 7-17 (2006)
29. Yao Z, Wei X, Wu X et al. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of tetrabenazine as VMAT2. Eur J. Med. Chem. 46(5), 1841-1848 (2011)
30. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a non-indole tranquilizing agent with reserpine-like effects. J Pharmacol. Exp. Ther. 127, 103-109 (1959)
31. Butcher LL, Anden NE. Effects of apomorphine and amphetamine on schedule-controlled behavior: reversal of tetrabenazine suppression and dopaminergic correlates. Eur J. Pharmacol. 6(3), 255-264 (1969)
32. Christmas AJ, Coulson CJ, Maxwell DR, Riddell D. A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors. Br. J Pharmacol. 45(3), 490-503 (1972)
33. Bagchi SP. Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine. Biochem. Pharmacol. 32(19), 2851-2856 (1983)
34. Pettibone DJ, Pflueger AB, Totaro JA. Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. Eur J. Pharmacol. 102(3-4), 431-436 (1984a)
35. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J. Pharmacol. 102(3-4), 425-430 (1984b)
36. Erickson JD, Eiden LE, Schafer MK, Weihe E. Reserpine-and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter. J Mol. Neurosci. 6(4), 277-287(1995)
37. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 27(7): 717-719 (1988)
38. Xenazine®, package insert, Lundbeck, Deerfield, IL, USA
39. Mehvar R, Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm. Sci. 76(6), 461-465 (1987)
40. Thibaut F, Faucheux BA, Marquez J et al. Regional distribution of monoamine vesicular uptake site in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using titrated tetrabenazine. Brain Res. 692, 233-243 (1995)
41. Kish SJ, Guttman M, Robitaille Y, el-Awar M, Chang LJ, Levey AI. Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1. Neurology 48(4), 1109-1111 (1997)
42. Bohnen NL, Koeppe RA, Meyer P, et al. Decreased striatal monoaminergic terminals in Huntington's disease. Neurology 54(9), 1753-1759 (2000)
43. Stahl SM, Meltzer HY. A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. J Pharmacol. Exp. Ther. 205(1), 118-132 (1978)
44. Rostene W, Boja JW, Scherman D, Carroll FI, Kuhar MJ. Dopamine transport: pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum. Eur J. Pharmacol. 218(1), 175-177 (1992)
45. Floor E, Leventhal PS, Wang Y, Meng L, Chen W. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J Neurochem. 64(2), 689-699(1995)
46. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19(6) 1271-1283 (1997)
47. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem. 47(2), 331-339 (1986)
48. Moriyama Y, Futai M. H(+)-ATPase, a primary pump for accumulation of neurotransmitters, is a major constituent of brain synaptic vesicles. Biochem. Biophys. Res. Commun. 173(1), 443-448 (1990)
49. Vander Borght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. [3H] methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68(3), 955-962 (1995)
50. Liu Y, Peter D, Roghani A et al. A cDNA that suppresses MPP+toxicity encodes a vesicular amine transporter. Cell 70(4), 539-551 (1992)
51. Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad. Sci. USA 89(22), 10993-10997 (1992)
52. Peter D, Finn JP, Klisak I et al. Chromosomal localization of the human vesicular amine transporter genes. Genomics 18(3), 720-723 (1993)
53. Surratt CK, Persico AM, Yang XD et al. A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs. FEBS Lett. 318(3), 325-330 (1993)
54. Weihe E, Schafer MK, Erickson JD, Eiden LE. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J Mol. Neurosci. 5(3), 149-164 (1994)
55. Gonzalez AM, Walther D, Pazos A, Uhl GR. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Mol. Brain Res. 22(1-4), 219-226 (1994)
56. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH. Differential expression of two vesicular monoamine transporters. J Neurosci. 15(9), 6179-6188 (1995)
57. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad. Sci. USA 93(10), 5166-5171 (1996)
58. Henry JP, Sagne C, Bedet C, Gasnier B. The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem. Int. 32(3), 227-246 (1998)
59. Cartier EA, Parra LA, Baust TB et al. A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J Biol. Chem. 285, 1957-1966 (2010)
60. Egaa LA, Cuevas RA, Baust TB et al. Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3. J Neurosci. 29, 4592-4604 (2009)
61. Brunk I, Blex C, Speidel D, Brose N, Ahnert-Hilger G. Ca2+-dependent activator proteins of secretion promote vesicular monoamine uptake. J Biol. Chem. 284, 1050-1056 (2009)
62. Brunk I, Blex C, Sanchis-Segura C et al. Deletion of Go2a abolishes cocaine-induced behavioral sensitization by disturbing the striatal dopamine content. FASEB J. 22, 3736-3746 (2008)
63. Requena DF, Parra LA, Baust TB et al. The molecular chaperone Hsc70 interacts with the vesicular monoamine transporter-2. J Neurochem. 110, 581-584 (2009)
64. Guillot TS, Miller GW. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 39, 149-170 (2009)
65. Taylor TN, Caudle WM, Miller GW. VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis. 21, 124-165 (2011)
66. Wang H, Chen X, Li Y, Tang TS, Bezprozvanny I. Tetrabenazine is neuroprotective in Huntington's disease mice. Mol. Neurodegener. 26(5), 18 (2010)
67. Scherman D, Jaudon P, Henry JP. Binding of a tetrabenazine derivative to the monoamine transporter of the chromaffin granule membrane. CR Seances Acad. Sci. III 293(4), 221-224 (1981)
68. Scherman D, Henry JP. The catecholamine carrier of bovine chromaffin granules. Form of the bound amine. Mol. Pharmacol. 23(2), 431-436 (1983)
69. Scherman D, Henry JP. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 25(1), 113-122 (1984)
70. Schuldiner S, Liu Y, Edwards RH. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J Biol. Chem. 268(1), 29-34 (1993)
71. Scherman D, Jaudon P, Henry JP. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc Natl Acad. Sci. USA 80(2), 584-588 (1983)
72. Near JA. [3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol. Pharmacol. 30(3), 252-257 (1986)
73. Darchen F, Scherman D, Desnos C, Henry JP. Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules. Biochem. Pharmacol. 37(22), 4381-4387 (1988)
74. Leysen JE, Eens A, Gommeren W, van Gompel P, Wynants J, Janssen PA. Identification of nonserotonergic [3H] ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin-and tetrabenazine-like drugs. J Pharmacol. Exp. Ther. 244(1), 310-321 (1988)
75. Darchen F, Scherman D, Henry JP. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28(4), 1692-1697 (1989)
76. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol. 12(3), 257-262 (1982)
77. Mehvar R, Jamali F, Watson MWB, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Drug Metab. Dispos. 15(2), 250-255 (1987b)
78. Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov. Disord. 22, 10-13 (2007)
79. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-a-[11C] dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb. Blood Flow Metab. 17(9), 919-931 (1997)
80. DaSilva JN, Kilbourn MR, Domino EF. In vivo imaging of monoaminergic nerve terminals in normal and MPTP-lesioned primate brain using positron emission tomography (PET) and [11C] tetrabenazine. Synapse 14(2), 128-131 (1993)
81. DeJesus OT, Shelton SE, Roberts AD, Nickles RJ, Holden JE. Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys. Synapse 44(4), 246-251 (2002)
82. DeMarchi N, Menella R. Huntington's disease and its association with psychopathology. Harvard Rev. Psychiatry 7(5), 278-289 (2000)
83. Paulsen JS, Ready RE, Hamilton JM et al. Neuropsychiatric aspects of Huntington's disease. J Neurol. Neurosurg. Psychiatry 71, 310-314 (2001)
84. Fog R, Pakkenberg H. Combined nitoman and pimizide treatment of Huntington's chorea and other hyperkinetic movement disorders. Acta Neurol. Scand. 16, 249-251 (1970)
85. Frank S, Ondo W, Fahn S et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin. Neuropharmacol. 31, 127-133 (2008)
86. Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov. Disord. 21, 1966-1972 (2006)
87. Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin. Pharmacother. 10, 2883-2896 (2009)
88. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J Med. 3, 1209-1223 (2005)
89. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H. Randomized controlled trial of the effect of quality of life of second-vs first-generation antipsychotic drugs in schizophrenia. Arch. Gen. Psychiatry 63, 1079-1087 (2006)
90. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov. Disord. 26, 147-152 (2011)
91. Kenney C, Hunter C, Mejia N, Davidson A, Jankovic J. Metoclopramide: an increasingly recognized cause of tardive dyskinesia. J Clin. Pharmacol. 48, 379-384 (2008)
92. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J Psychiatry 156, 1279-1281 (1999)
93. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 45(4), 525-531(2011)
94. Jankovic J, Kurlan R. Tourette Syndrome: evolving concepts. Mov. Disord. 26, 1149-1156 (2011)
95. Kenney C, Hunter C, Mejia N, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J Ped. Neurol. 5, 9-13 (2007)
96. Porta M, Sassi M, Cavallazzi M et al. Tourette's syndrome and role of tetrabenazine: review and personal experience. Clin. Drug Investig. 28, 443-459 (2008)
97. Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. J Child Neurol. 23, 435-437 (2008)
98. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov. Disord. 11(1), 95 (1966)
99. Burke RE. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 31(8), 1022-1025 (1981)
100. Mateo D, Munoz-Blanco JL, Giménez-Roldán S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin. Neuropharmacol. 15(1), 63-68 (1992)
101. Snaith RP, Warren HD. Letter: treatment of Huntington's chorea with tetrabenazine. Lancet 1(7854), 413-414 (1974)
102. Huang CY, McLeod JG, Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington's chorea. Med. J Aust. 1(16), 583-584 (1976)
103. Anderson KE, Gehl CR, Marder KS, Beglinger LJ, Paulsen JS. Huntington's Study Group. Comorbidities of obsessive and compulsive symptoms in Huntington's disease. J Nerv. Ment. Dis. 5, 334-338 (2010)
104. Kidd DW, McLellan DL. Self-poisoning with tetrabenazine. Br. J Clin. Pract. 26(4), 179-180 (1972)
105. Dietrichs E, Magnusson A, Opjordsmoen S. Acute dystonia caused by tetrabenazine what does it tell us about pathophysiology. Eur J. Neurol. 3, 395-396 (1996)
106. Burke RE. Reches A, Traub MM, Ilson J, Swash M, Fahn S. Tetrabenazine induces acute dystonic reactions. Ann Neurol. 17, 200-202 (1985)
107. Poon LH. Role of tetrabenazine for Huntington's disease -associated chorea. Ann Pharmacother. 44(6), 1080-1089 (2010)
108. Palao AM, Mostile G, Hunter CB, Jankovic J. Assessing patients' access to tetrabenazine (Xenazine) after FDA approval. Mov. Disord. (Suppl. 2), S275 (2010)
109. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C] dihydrotetrabenazine. J Cereb. Blood Flow Metab. 19(12), 1376-1384 (1999)